Cignon

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cignon

Property Description
Active Ingredients Chondroitin Sulfate, Collagen Type I, Hyaluronic Acid, Vitamin C, and minerals
Form Soft Capsules and Liquid Vials (Shots)
Pharmacological Class Nutraceutical / Connective Tissue Support Agent
Common Use Nutritional support for tendon and ligament integrity
Origin Blend of Derived biological and isolated Synthetic components

What Type of Product is Cignon?

Cignon is classified as a dietary supplement and functions as a specialized nutraceutical, a non-prescription product providing specific health benefits beyond basic nutrition. It belongs to the functional category of a connective tissue support agent, whose primary role is to supply structural materials and cofactors essential for the body's supporting tissues. As a branded product, Cignon is often highlighted for its unique positioning toward tendon and ligament health. It is prepared for oral intake, being available in distinct dosage form(s) such as Soft Capsules and Liquid Vials (Shots).


Cignon's Multi-Component Composition and Origin

The product is a combination product that integrates several key components. Its structural foundation includes the mucopolysaccharides Chondroitin Sulfate and Hyaluronic Acid, alongside Hydrolyzed Collagen Type I fragments, which are key proteins in connective tissue. The formula is enriched with essential micronutrients, notably Vitamin C (L-Ascorbic Acid) and the minerals Manganese, Zinc, and Copper. The inclusion of Vitamin C is highly relevant, as it is required for the biosynthesis of collagen. This indicates the formula provides a crucial element necessary for the body's natural processes of structural maintenance. The product’s origin is a combination of derived biological materials and isolated synthetic nutrients.


General Purpose: Supporting Tendon and Ligament Integrity

The overarching purpose of Cignon is to provide necessary nutritional support for the proper maintenance and function of connective tissues, including tendons, ligaments, and fascia. By supplying specific building blocks and enzymatic cofactors, the product supports the body’s natural renewal processes. Components like Collagen and related structural compounds provide support for the structural integrity of soft connective tissues. This indicates the product's components are relevant for promoting the overall health and condition of the musculoskeletal framework.

What side effects are possible with Cignon?

Possible Side Effects and Safety Information

The safety profile for Cignon, a nutraceutical composed of Chondroitin Sulfate, Collagen Type I, Hyaluronic Acid, and Vitamin C, is defined by the established regulatory documentation of its individual components.


Official Adverse Reaction Categories

Adverse events are generally mild and are officially categorized by System-Organ Class and frequency. The most frequently documented reactions fall under Gastrointestinal disorders.

Classification System-Organ Class Description
Common Gastrointestinal disorders Mild stomach upset, bloating, or minor changes in bowel habits (e.g., constipation or diarrhea).
Rare Immune system disorders Potential for hypersensitivity reactions, which may manifest as skin and subcutaneous tissue disorders (e.g., rash or itching).

Safety Considerations and Limitations

While most effects are common and non-serious, regulatory documents note specific safety constraints related to component activity and special populations:

  • Serious Reactions: The risk of rare, severe anaphylactic reactions is noted for components of biological origin. Additionally, the component Vitamin C is associated with the official caution regarding the potential for kidney stone formation (nephrolithiasis) in susceptible individuals at extremely high, unstated intakes.

  • Interactions: Chondroitin Sulfate carries a regulatory note regarding its potential to enhance the effects of anticoagulant medications such as Warfarin, which requires caution due to the high-level risk of bleeding.

  • Population Cautions: Safety is not conclusively established for individuals who are pregnant or breastfeeding, requiring regulatory caution. Furthermore, caution is associated with the use of Chondroitin components in individuals with diabetes due to the potential for minor effects on blood glucose levels. Official labeling may also include a note for individuals with shellfish allergy depending on the source material.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory information concerning the overdose profile of Cignon is governed by its classification as a multi-component dietary supplement (Nutraceutical). This product class is not subject to the same regulatory requirements as prescription medications. Consequently, Cignon is not required to possess a formal, government-approved regulatory label, such as an FDA Prescribing Information or an EMA Summary of Product Characteristics (SmPC), that mandates a specific section detailing official overdose symptoms and management protocols.


Overdose scope (Official Regulatory Status)

Feature Official Regulatory Statement
Documented overdose presentations None. No specific symptom clusters are documented in a formal regulatory overdose section for this finished product.
Physiological systems affected None. No systems are officially listed in a required regulatory document for this product.
Emergency-response statements None. No mandated emergency actions are specified in a formal regulatory overdose section for Cignon.

Overdose Classifications

Classification Official Regulatory Statement
Severity classification None. No severity classification is defined in an official regulatory document for Cignon.
Regulatory basis Not applicable. Does not possess a required regulatory drug label for overdose classification.

Resulting overdose structure

  • No specific clinical manifestations of overdose are documented in a formal regulatory prescribing information section (SmPC/FDA Prescribing Information) for the finished product Cignon.
  • No official emergency actions, such as "seek immediate medical attention," are explicitly mandated by regulatory authorities for Cignon overdose, as this product does not have a required drug label overdose section.
  • The product does not possess an official, government-approved overdose profile detailing supportive measures, monitoring requirements, or the existence of a specific antidote.

Connection to the overall overdose profile: The regulatory overdose profile for Cignon is defined by the absence of a specific section mandated by government medicines authorities for this product class. If overconsumption of Cignon is suspected, or if any severe, unexpected, or adverse physiological symptoms occur, immediate professional medical attention must be sought. This action is consistent with general safety principles required when managing potentially excessive intake of any product.

Therapeutic Uses of Cignon

Cignon is a specialized nutraceutical and connective tissue support agent, with its primary use being to supply nutritional support for the maintenance of soft connective tissues. This product provides supportive benefit across several key areas related to musculoskeletal health and function. Essential nutrients within the formula provide supportive benefits in contexts involving soft connective tissue health, aligning with the product’s foundational purpose.


Key Areas of Nutritional Support

Cignon is commonly used to provide nutritional support in contexts involving the structural maintenance of tendons and ligaments; is used for managing discomfort and aching in soft tissues; and as adjunctive support during recovery and rehabilitation phases. It is applied in scenarios characterized by symptoms related to physical discomfort and functional stiffness, particularly those linked to physical strain, high activity levels, or age-related changes.

“Providing nutritional support for healthy tissue structure may assist in easing the symptom burden and supporting flexibility.”

This supportive focus helps improve day-to-day comfort during periods when symptoms interfere with routine activities.


Quick Fact: Support for Soft Tissue Discomfort
Cignon is relevant for individuals seeking additional symptomatic assistance in contexts involving heightened physiological stress, such as post-training recovery or age-related decline.

Regulatory References

  1. NIH MedlinePlus Medical Encyclopedia overview on Vitamin C

Eligibility and Restrictions for Use

The eligibility profile for Cignon, a multi-component dietary supplement, is defined by regulatory principles concerning hypersensitivity, age, and concurrent health conditions. Standard use is permitted for healthy adults 18 years and older.

Eligibility Status Population/Condition
Contraindicated Individuals with a known hypersensitivity or allergy to any active ingredient (Collagen, Chondroitin Sulfate, Hyaluronic Acid, etc.) or excipient.
Not Recommended Children and adolescents (under 18 years), pregnant women, and breastfeeding women.

Official documents classify use in children and adolescents as not established due to insufficient reliable safety data. Similarly, use during pregnancy and lactation is generally not recommended.

Specific restrictions advise caution or avoidance based on medical history. Use is restricted and requires clinical oversight for individuals concurrently taking anticoagulant therapy (e.g., Warfarin), due to potential risks from the Chondroitin Sulfate component. Furthermore, the product should be avoided by patients with or at high risk for prostate cancer, and used with caution in individuals with asthma, until further regulatory clarity is established.

What should I know about interactions with other medicines?

Cignon Interactions with other medicines and products

Official medicinal product regulatory documents from major governmental bodies, such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), do not provide a publicly accessible drug-drug interaction (DDI) profile for a regulated pharmaceutical product named Cignon. Consequently, there are no specific official statements regarding mechanistic drug interactions, substance categories to be avoided, or population-specific interaction restrictions.

Since no specific regulatory label or Summary of Product Characteristics (SmPC) is publicly available to define Cignon's interaction risk, specific advice on co-administration with other medicines, including over-the-counter products, is not documented in authoritative drug labeling sources.

Pharmacokinetic interactions typically involve key enzymes (e.g., Cytochrome P450, or CYP), drug transporters (e.g., P-glycoprotein), or changes in gastrointestinal absorption. Without an official label, Cignon's status as a substrate, inhibitor, or inducer of these critical pathways cannot be definitively established from public governmental sources.

Patients should be aware that the general principles of polypharmacy suggest that the co-administration of any product with other medicines, supplements, or foods has the potential to alter effectiveness or safety. However, any clinical determination of interaction risk for Cignon must rely on its components and must be provided by a qualified healthcare professional.

Mechanism of Action

Cignon's mechanism involves coordinated structural and enzymatic support critical for the anabolism and chemical stabilization of dense connective tissue like tendons and ligaments. It operates primarily through two synergistic mechanistic domains.


Substrate Supply and Tissue Resilience

This domain focuses on the physical provision of Extracellular Matrix (ECM) precursors—specifically Hydrolyzed Collagen peptides, Chondroitin Sulfate, and Hyaluronic Acid. By supplying these fundamental building blocks, the mechanism facilitates tenocyte uptake and accelerates the biosynthesis and assembly of new tissue structure. The incorporated GAGs simultaneously enhance tissue hydration and viscoelasticity, which are the physiological basis for the tissue's mechanical resilience to load and deformation.


Enzymatic Stabilization and Matrix Homeostasis

This domain involves the critical function of micronutrients as enzymatic cofactors and anti-catabolic modulators. Vitamin C and Copper enable the essential hydroxylation and cross-linking of newly synthesized collagen via enzymes like Prolyl Hydroxylase and Lysyl Oxidase. This chemical stabilization process is necessary for achieving enhanced tensile strength. Furthermore, components like Chondroitin Sulfate help maintain Matrix Homeostasis by modulating catabolic enzyme activity (MMPs), which limits the enzymatic degradation of existing structural integrity.

Dosage and Administration Information

How Cignon is Used: Official Administration Guidelines

Cignon is classified as a nutraceutical and dietary supplement designed for oral intake. Its official usage instructions are guided by established safety standards for its key components, such as Chondroitin Sulfate.


Official Administration and Dosage

Cignon is available in two oral dosage forms: Soft Capsules and Liquid Vials (Shots). The administration is intended for self-management in an outpatient setting.

The standard approach involves taking the defined daily serving once daily. The dose is typically formulated to deliver structural components within safe intake levels, such as up to 1,200 mg/day of the Chondroitin Sulfate component. Consumption is often recommended to be taken with or immediately after food to help ensure optimal gastrointestinal tolerance.


Usage Duration and Constraints

As a product providing nutritional support for structural maintenance, Cignon is intended for extended, long-term use, which may span periods of up to two years or longer.

Official instructions place specific constraints on use for certain populations due to a lack of dedicated safety data:

Population Group Administration Rule Regulatory Principle
Pediatric Use Not recommended Lack of established safety and dosing data
Pregnancy/Lactation Not recommended Lack of sufficient and reliable safety data

The standard procedure in the event of a missed dose is to simply resume the normal once-daily schedule the following day, without attempting to double the amount.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cignon

The information below summarizes the types of research conducted on the components of Cignon, which is classified as a connective tissue support agent. This overview is based on scientific reports and does not constitute medical advice or a recommendation for use.


Evidence Overview for Chronic Tendon Conditions (Tendinopathy)

This section summarizes the structure of available clinical research, primarily focusing on Randomized Controlled Trials (RCTs) and systematic reviews that have examined Cignon's components in studies exploring nutritional support during the rehabilitation phase for chronic tendon overload or injuries. These short-term RCTs typically compared the supplement components, often used alongside a structured exercise program, against a placebo given with the same exercise.

Research examined how symptom intensity or variability changed over defined time intervals, recording measurements on functional scales and general pain scores. The evidence level is broadly characterized as Moderate in consistency. It is still uncertain how much of the observed change is related to the supplement alone, as findings were often derived from populations studied in conjunction with an exercise program.


Evidence Overview for Musculoskeletal Discomfort and Stiffness

Studies explored symptomatic and functional outcomes in populations such as older adults experiencing age-related changes and individuals with related joint conditions. These trials investigated the use of Cignon's components in studies exploring general musculoskeletal discomfort and functional stiffness associated with soft tissues. Studies monitored how patients reported their perceived discomfort and examined functional outcomes using scales that measure daily functioning or activity level.

Findings were mixed across the research, and the evidence is limited by the fact that trials often included patients already receiving other therapies. Data for certain groups remain insufficient, and variability in the exact supplement form and dosing across the research makes direct comparison challenging. The evidence quality varies across studies, leading to a Moderate assessment for this area.


Research into Connective Tissue Biosynthesis

Research describes the fundamental role of ingredients like Vitamin C in collagen synthesis, which was then explored in studies of the supplement components. Studies monitored rates of tendon protein synthesis and specific biomarkers of collagen synthesis in contexts involving temporary physiological imbalance. The evidence level is broadly characterized as High for research describing the component's role in the collagen synthesis process itself.

In contrast, certainty remains low regarding the direct clinical effect of these changes in biomarkers on final, long-term human outcomes like actual tissue strength or sustained functional change. Research highlights what is known—and what is still uncertain—as these findings rely heavily on short-term data, animal models, or indirect measurements.

Key Studies & References

  1. Vitamin C - Medical Encyclopedia (MedlinePlus)

Frequently Asked Questions (FAQ)

Common questions about Cignon (FAQ)

Q: Are there any long-term side effects associated with Cignon?

A: Studies on the main components of Cignon, such as Chondroitin Sulfate, have examined use over extended durations of up to six years. The evidence indicates that the components have generally been well-tolerated over this time. Commonly reported effects typically include minor stomach upset or nausea.


Q: What are the major contraindications for Cignon? (who definitely cannot use it)

A: Official safety information indicates that Cignon is not recommended for individuals with a known hypersensitivity or allergy to its ingredients, which may include shellfish allergy depending on the component's source. Regulatory caution is associated with a noted risk of increased bleeding when used alongside anticoagulant medications, such as Warfarin.


Q: Can I take Cignon if I am taking vitamins or herbal products?

A: Safety reviews of Cignon’s main component generally report no listed major interactions with other standard vitamins or herbal supplements. While no specific major risk is identified, general guidance emphasizes the importance of sharing information about all products being taken with a qualified healthcare professional.


Q: Are there any specific organs Cignon may affect, like the kidneys?

A: Official caution is specifically associated with the kidneys due to the Vitamin C component within Cignon. At extremely high intake levels, Vitamin C has a noted theoretical potential for contributing to kidney stone formation in individuals already susceptible to this condition.


Q: Is Cignon a controlled substance?

A: Cignon is classified by regulatory authorities as a non-prescription dietary supplement and nutraceutical, rather than a pharmaceutical drug. For this reason, Cignon does not contain any ingredients that are currently classified as a controlled substance by major regulatory agencies.


Q: Will Cignon interfere with my birth control pills?

A: According to drug interaction summaries, there is no known severe, serious, or moderate interaction reported between the structural components of Cignon and oral contraceptive medications. Individuals who have concerns about any potential interference should seek informational guidance from a qualified health professional.


Q: Is Cignon covered by most insurance plans?

A: Since Cignon is classified as a non-prescription dietary supplement and nutraceutical, rather than a regulated pharmaceutical drug, it is generally not covered by standard medical insurance plans or formularies. Coverage may vary based on specific plan details.


Q: Is Cignon addictive?

A: Official safety profiles for the components of Cignon indicate that the product has no known potential for abuse, dependence, or addiction.


Q: Does Cignon show up on a standard drug test?

A: The ingredients in Cignon are not scheduled substances or illegal drugs. Therefore, the product's components are generally not included in or tested for on standard workplace or athletic drug panels.


Q: Does Cignon have any common psychological side effects?

A: The documented common and rare adverse events for the product's components are overwhelmingly physical, such as gastrointestinal upset or skin reactions. There are no common psychological or behavioral side effects officially reported in the regulatory safety summaries.


Q: Does Cignon cause high blood pressure?

A: Official safety documentation does not list high blood pressure as a common or frequently occurring side effect. Any concerns about blood pressure should be discussed with a healthcare provider.


Q: Does Cignon affect cholesterol levels?

A: Scientific literature has explored the relationship between the main component of Cignon and cholesterol, but it is not listed as a primary effect of Cignon.


Q: Is Cignon known to cause weight gain or loss?

A: Official safety documents and component research summaries do not list significant weight gain or loss as a documented side effect of Cignon. Studies of the main component, Chondroitin Sulfate, have not established a link suggesting it causes weight gain.


Q: Can Cignon make you feel tired or drowsy?

A: Official documentation and safety summaries for the main components of Cignon primarily list physical side effects, such as mild stomach discomfort. There is no frequent or common reporting of central nervous system (CNS) effects like drowsiness or fatigue.


Q: Are headaches a common side effect of Cignon?

A: Official documentation lists common adverse events primarily in the gastrointestinal category, such as bloating and stomach pain. Although generalized consumer reports occasionally mention headaches, they are not typically classified as a common or frequent side effect in the official safety profile for the product's components.


Q: Can Cignon affect my ability to drive or operate machinery?

A: No official regulatory warnings specifically advise against driving or operating machinery. However, individuals should be aware that mild side effects, like headache or fatigue, are possible with any product. It is informational that individuals assess their personal tolerance before performing tasks that require full mental alertness.

How should Cignon be stored and disposed of?

How to Store and Dispose of Cignon

Storage and disposal must strictly adhere to regulatory guidelines to ensure product stability and safety, as mandated by official health authorities.

Storage Conditions

Cignon must be stored at controlled room temperature (e.g., below 25 C or 30 C). The product must be protected from light and moisture, requiring that it be stored in its original container and that the container remains tightly closed. It is critical that the product is not refrigerated or frozen to prevent damage to the dosage forms.

Safety and Disposal

For child safety, Cignon must be stored out of the sight and reach of children. Unused or expired Cignon must be disposed of in accordance with local pharmaceutical waste requirements. To protect the environment, the product must not be disposed of in wastewater or ordinary household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cignon found in:

A-Z Index: